Inventor · disambiguated record
James D. Otvos
Also filed as: OTVOS JAMES D
41 granted patents·10 pending applications·734 citations·filing 1988–2024
98Inventor score
Top patents by PatentIndex Score
51 records- 0197US5343389AMethod and apparatus for measuring classes and subclasses of lipoproteinsUNIV NORTH CAROLINA STATE·Filed 1993·Granted Aug 30, 1994·196 cites·14 claims
- 0295US7790465B2Methods, systems and computer programs for assessing CHD risk using adjusted LDL particle number measurementsLIPOSCIENCE INC·Filed 2006·Granted Sep 7, 2010·29 cites·38 claims
- 0394US8013602B2NMR clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamplesLIPOSCIENCE INC·Filed 2005·Granted Sep 6, 2011·32 cites·50 claims
- 0494US6576471B2Methods, systems, and computer program products for analyzing and presenting NMR lipoprotein-based risk assessment resultsLIPOSCIENCE INC·Filed 2001·Granted Jun 10, 2003·92 cites·49 claims
- 0594US6518069B1Methods and computer program products for determining risk of developing type 2 diabetes and other insulin resistance related disordersLIPOSCIENCE INC·Filed 2000·Granted Feb 11, 2003·81 cites·45 claims
- 0694US4933844AMeasurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometerOTVOS JAMES D·Filed 1988·Granted Jun 12, 1990·106 cites·12 claims
- 0793US6617167B2Method of determining presence and concentration of lipoprotein X in blood plasma and serumLIPOSCIENCE INC·Filed 2002·Granted Sep 9, 2003·61 cites·15 claims
- 0890US8704521B2NMR analyzers for clinical evaluation of biosamplesOTVOS JAMES D·Filed 2011·Granted Apr 22, 2014·8 cites·27 claims
- 0989US9928345B2Multiple-marker risk parameters predictive of conversion to diabetesLIPOSCIENCE INC·Filed 2015·Granted Mar 27, 2018·3 cites·23 claims
- 1088US11231429B2Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameterLIPOSCIENCE INC·Filed 2018·Granted Jan 25, 2022·2 cites·11 claims
- 1188US10613044B2NMR quantification of TMAOLIPOSCIENCE INC·Filed 2016·Granted Apr 7, 2020·2 cites·14 claims
- 1288US10504610B2Methods, systems and computer programs for assessing CHD risk using adjusted HDL article number measurementsLIPOSCIENCE INC·Filed 2016·Granted Dec 10, 2019·2 cites·20 claims
- 1388US10388414B2Multi-parameter diabetes risk evaluationsLIPOSCIENCE INC·Filed 2016·Granted Aug 20, 2019·6 cites·20 claims
- 1488US9541620B2NMR quantification of TMAOLIPOSCIENCE INC·Filed 2013·Granted Jan 10, 2017·5 cites·24 claims
- 1587US10365339B2NMR analyzers for clinical evaluation of biosamplesLIPOSCIENCE INC·Filed 2014·Granted Jul 30, 2019·5 cites·28 claims
- 1687US8386187B2Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating sameLIPOSCIENCE INC·Filed 2009·Granted Feb 26, 2013·14 cites·29 claims
- 1787US2024302389A1Cardiovascular Risk Evaluations Using a Risk Parameter That Includes an HDL and Inflammatory Biomarker Interaction ParameterLIPOSCIENCE INC·Filed 2024·Application pending·0 cites
- 1887US2024296902A1Methods, Systems and Computer Programs for Assessing CHD Risk Using Adjusted HDL Particle Number MeasurementsLIPOSCIENCE INC·Filed 2024·Application pending·0 cites
- 1986US9952232B2Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameterLIPOSCIENCE INC·Filed 2015·Granted Apr 24, 2018·4 cites·22 claims
- 2086US9792410B2Multi-parameter diabetes risk evaluationsLIPOSCIENCE INC·Filed 2013·Granted Oct 17, 2017·10 cites·25 claims
- 2186US2024125719A1NMR Quantification of TMAOLIPOSCIENCE INC·Filed 2023·Application pending·0 cites
- 2285US10386355B2CHD risk stratification evaluations for subjects with high levels of large HDL-PLIPOSCIENCE INC·Filed 2016·Granted Aug 20, 2019·3 cites·18 claims
- 2385US9361429B2Multi-parameter diabetes risk evaluationsLIPOSCIENCE INC·Filed 2013·Granted Jun 7, 2016·17 cites·52 claims
- 2483US9435870B2Methods, systems and computer programs for assessing CHD risk using adjusted HDL particle number measurementsOTVOS JAMES D·Filed 2007·Granted Sep 6, 2016·6 cites·33 claims
- 2582US11156685B2NMR analyzers for clinical evaluation of biosamplesLIPOSCIENCE INC·Filed 2019·Granted Oct 26, 2021·1 cites·16 claims
- 2681US9535144B2NMR quantification of TMAOLIPOSCIENCE INC·Filed 2013·Granted Jan 3, 2017·3 cites·22 claims
- 2781US9483612B2CHD risk stratification evaluations for subjects with high levels of large HDL-PLIPOSCIENCE INC·Filed 2013·Granted Nov 1, 2016·4 cites·40 claims
- 2881US2024096497A1Multi-Parameter Diabetes Risk EvaluationsLIPOSCIENCE INC·Filed 2023·Application pending·0 cites
- 2981US2025012820A1Multi-parameter metabolic vulnerability index evaluationsLIPOSCIENCE INC·Filed 2024·Application pending·0 cites
- 3081US2024304336A1Multiple-Marker Risk Parameters Predictive of Conversion to DiabetesLIPOSCIENCE INC·Filed 2024·Application pending·0 cites
- 3180US11988679B2Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameterLIPOSCIENCE INC·Filed 2022·Granted May 21, 2024·0 cites·30 claims
- 3280US11156621B2Multi-parameter metabolic vulnerability index evaluationsLIPOSCIENCE INC·Filed 2018·Granted Oct 26, 2021·2 cites·29 claims
- 3380US9470771B2NMR measurements of NMR biomarker GlycALIPOSCIENCE INC·Filed 2013·Granted Oct 18, 2016·10 cites·8 claims
- 3480US6653140B2Methods for providing personalized lipoprotein-based risk assessmentsLIPOSCIENCE INC·Filed 2002·Granted Nov 25, 2003·23 cites·23 claims
- 3578US11037683B2Multiple-marker risk parameters predictive of conversion to diabetesLIPOSCIENCE INC·Filed 2018·Granted Jun 15, 2021·1 cites·20 claims
- 3678US9483611B2Protective HDL particle number evaluationsLIPOSCIENCE INC·Filed 2013·Granted Nov 1, 2016·2 cites·18 claims
- 3777US10852293B2NMR measurements of NMR biomarker GlycALIPOSCIENCE INC·Filed 2016·Granted Dec 1, 2020·2 cites·12 claims
- 3876US11942187B2Methods, systems and computer programs for assessing CHD risk using adjusted HDL particle number measurementsLIPOSCIENCE INC·Filed 2019·Granted Mar 26, 2024·0 cites·11 claims
- 3975US11990243B2Multiple-marker risk parameters predictive of conversion to diabetesLIPOSCIENCE INC·Filed 2021·Granted May 21, 2024·0 cites·20 claims
- 4074US11703501B2CHD risk stratification evaluations for subjects with high levels of large HDL-PLIPOSCIENCE INC·Filed 2019·Granted Jul 18, 2023·0 cites·20 claims
- 4174US2022043086A1NMR Analyzers for Clinical Evaluation of BiosamplesLIPOSCIENCE INC·Filed 2021·Application pending·0 cites
- 4273US12130295B2NMR system and methods for multi-parameter metabolic vulnerability index evaluationsLIPOSCIENCE INC·Filed 2021·Granted Oct 29, 2024·0 cites·19 claims
- 4373US11782002B2NMR quantification of TMAOLIPOSCIENCE INC·Filed 2020·Granted Oct 10, 2023·0 cites·19 claims
- 4469US11692995B2NMR measurements of NMR biomarker GlycALIPOSCIENCE INC·Filed 2020·Granted Jul 4, 2023·0 cites·19 claims
- 4568US11710568B2Multi-parameter diabetes risk evaluationsLIPOSCIENCE INC·Filed 2019·Granted Jul 25, 2023·0 cites·26 claims
- 4667US2023024795A1Methods and Systems to Detect and Quantify the Amount of LP-X and Other Abnormal Lipoproteins in a Biosample Using NMR SpectroscopyLIPOSCIENCE INC·Filed 2022·Application pending·0 cites
- 4765US2024044826A1Metabolic vulnerability analyzed by nmrLIPOSCIENCE INC·Filed 2023·Application pending·0 cites
- 4861US11467171B2Methods and systems to detect and quantify the amount of LP-X and other abnormal lipoproteins in a biosample using NMR spectroscopyLIPOSCIENCE INC·Filed 2018·Granted Oct 11, 2022·0 cites·20 claims
- 4947US11124837B2Methods and systems for predicting colorectal cancer incidence and mortalityLIPOSCIENCE INC·Filed 2017·Granted Sep 21, 2021·0 cites·17 claims
- 5045US2022011388A1Methods to predict liver disease mortality using lipoprotein lp-zLIPOSCIENCE INC·Filed 2019·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when James D. Otvos files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →